The Johnson & Johnson sunscreen lawsuit over benzene contamination in Neutrogena and Aveeno aerosol products is unresolved. A proposed class action settlement that would have paid full refunds for recalled products and roughly $5 vouchers for related purchases was approved in 2023, then vacated by the Eleventh Circuit in June 2024. The renewed settlement motion is pending before the same federal judge in Florida, and no consumer claims can be filed while it sits unapproved. Separate personal injury cases alleging that benzene exposure caused cancer are moving on their own track, and at least one has already settled confidentially.
What Products Were Recalled and Why
On July 14, 2021, Johnson & Johnson Consumer Inc. issued a voluntary recall of all lots of five aerosol sunscreen product lines: Neutrogena Beach Defense, Neutrogena Cool Dry Sport, Neutrogena Invisible Daily Defense, Neutrogena Ultra Sheer, and Aveeno Protect + Refresh.1Johnson & Johnson. Johnson & Johnson Consumer Inc. Issues Voluntary Recall of Specific Neutrogena and Aveeno Aerosol Sunscreen Products The recall followed a May 24, 2021 citizen petition from Valisure, an independent analytical pharmacy that had tested 294 batches of sunscreen and after-sun products from 69 brands and reported detectable benzene in 78 batches, with 14 exceeding the 2 parts-per-million threshold the FDA conditionally recognizes for trace solvent contamination in drug products.2Regulations.gov. Valisure Citizen Petition on Benzene in Sunscreen Products
Benzene is not a sunscreen ingredient. The FDA has identified inactive components as likely sources of contamination in aerosol drug products, particularly carbomers historically manufactured with benzene as a solvent, and isobutane spray propellants.3FDA. Frequently Asked Questions on Benzene Contamination in Drugs Benzene is classified as a known human carcinogen by the International Agency for Research on Cancer, and chronic exposure is linked to leukemia and other blood cancers. J&J said the contamination was not intentional and characterized the recall as taken “out of an abundance of caution,” stating that daily use at the levels detected “would not be expected to cause adverse health consequences.”4FDA. Johnson & Johnson Consumer Inc. Issues Voluntary Recall of Specific Neutrogena and Aveeno Aerosol Sunscreen Products
The Consumer Class Action and $5 Voucher Settlement
Lawsuits began within days of Valisure’s petition. On October 8, 2021, the Judicial Panel on Multidistrict Litigation consolidated the cases as In re: Johnson & Johnson Aerosol Sunscreen Marketing, Sales Practices and Products Liability Litigation, MDL No. 3015, assigned to Judge Anuraag Singhal in the Southern District of Florida.5Judicial Panel on Multidistrict Litigation. MDL-3015 Transfer Order The consolidated claims included negligence, strict product liability, consumer fraud, breach of warranty, failure to warn, and fraudulent concealment.6JoinTheMany.com. Benzene Lawsuit
On December 17, 2021, the parties moved for preliminary approval of a class settlement. Consumers who bought the recalled aerosol products would receive a full refund. Consumers who bought non-recalled sunscreens allegedly containing benzene would receive vouchers worth roughly $5 toward a future Johnson & Johnson purchase. Plaintiffs’ attorneys negotiated a $2.6 million cash fee award, which J&J agreed not to oppose.7HLLI. In re Johnson & Johnson Sunscreen Litigation Judge Singhal granted preliminary approval in March 2022 and final approval on February 27, 2023.8U.S. District Court, Southern District of Florida. 21-MD-3015-Singhal – In Re Johnson & Johnson Aerosol Sunscreen Litigation
Why the Eleventh Circuit Vacated the Settlement
Theodore H. Frank, director of the Center for Class Action Fairness, objected and appealed. His central argument was that the $5 vouchers were “coupons” under the Class Action Fairness Act, not real compensation, because they were not worth enough to cover the retail price of any J&J sunscreen on their own. Under CAFA, attorney fees in coupon settlements must be scaled to the actual redemption rate, and Frank argued the lawyers’ $2.6 million cash award dwarfed what class members would actually receive. He also challenged whether the named plaintiffs had standing to seek the injunctive relief in the deal, which required J&J to purge inventory containing certain aerosol propellants and adopt new benzene testing protocols.9HLLI. Frank Response and Reply Brief
On June 20, 2024, the Eleventh Circuit vacated the approval in a per curiam opinion. The court relied on two recent decisions. Drazen v. Pinto (2024) established that dollar-amount vouchers redeemable only against a defendant’s own products are “coupons” under CAFA, meaning Judge Singhal had to evaluate the deal under the stricter standards CAFA imposes on coupon settlements. Williams v. Reckitt Benckiser LLC (2023) held that a desire to buy hypothetical improved products in the future is too speculative to establish standing for injunctive relief. The appeals court sent the case back with instructions to reevaluate the settlement under both frameworks.10GovInfo. Eleventh Circuit Opinion, Case Nos. 23-11319 & 23-11541
Where the Settlement Stands Now
On remand, the settling parties filed a renewed motion for final approval. As of July 3, 2025, Frank filed an opposition to that renewed motion, and the matter remains pending before Judge Singhal.7HLLI. In re Johnson & Johnson Sunscreen Litigation No class members can file claims or receive refunds or vouchers while the settlement sits unapproved. If Judge Singhal reapproves the deal, a new claims window and notice period would follow. If he rejects it, the parties would either renegotiate or the underlying MDL would resume toward trial.
Personal Injury Lawsuits Over Cancer
The class action covers economic losses tied to product purchases. It does not resolve claims by people who say benzene in the sunscreens caused them serious illness. Those cases move individually.
In April 2023, a father filed suit in a North Carolina federal court alleging his 14-year-old son died of acute myeloid leukemia in April 2021 after prolonged exposure to J&J’s benzene-contaminated sunscreen. Johnson & Johnson settled the case in August 2024 on undisclosed terms.11Lawsuit Information Center. Sunscreen Recall Lawsuit Payouts
In September 2023, Kristi Hazard filed suit in the Central District of California on behalf of her then-13-year-old daughter, P.H., who was diagnosed with acute myeloid leukemia in 2020 after what the complaint described as regular weekly use of Neutrogena Beach Defense and Ultra Sheer aerosol sunscreens from 2010 to 2021. Johnson & Johnson moved to dismiss, arguing the complaint lacked specific details such as lot numbers and SPF levels. In December 2023, Judge Percy Anderson rejected the motion, ruling that the plaintiff had “plausibly” alleged that the products she used contained benzene, that her use exposed her to it, and that the exposure caused her leukemia. The case was cleared for discovery.12AboutLawsuits.com. Neutrogena Sunscreen Lawsuit AML to Move Forward
Personal injury plaintiffs typically seek damages for medical expenses, lost income, and pain and suffering, which are not available through the class settlement’s refund-and-voucher structure. Anyone who believes benzene exposure from a recalled sunscreen contributed to a cancer diagnosis would generally pursue an individual claim rather than wait for the class deal.
Who Is Liable After the Kenvue Spin-Off
In August 2023, Johnson & Johnson completed the spin-off of its consumer health division into Kenvue Inc., a new publicly traded company. Neutrogena and Aveeno are now part of the Kenvue brand portfolio.13Kenvue Inc. Kenvue Becomes a Fully Independent Company Under the separation agreement filed with the SEC, liabilities related to the former consumer health segment were allocated to Kenvue, with Kenvue required to indemnify J&J. The specific placement of pending sunscreen lawsuits depends on unpublished schedules to the agreement that designate which entity handles each matter.14SEC. Kenvue Separation Agreement Johnson & Johnson retained a 9.5 percent stake in Kenvue after the separation. For consumers, the practical point is that the corporate defendant and indemnitor picture has changed since the recall, and case captions and settlement documents may name either or both companies going forward.